Compare Stocks

Date Range: 

 Supernus PharmaceuticalsADC TherapeuticsIronwood PharmaceuticalsMyovant SciencesHeron Therapeutics
SymbolNASDAQ:SUPNNYSE:ADCTNASDAQ:IRWDNYSE:MYOVNASDAQ:HRTX
Price Information
Current Price$29.38$21.60$10.99$19.76$18.48
52 Week RangeBuyBuyHoldBuyBuy
MarketRank™
Overall Score1.91.71.61.31.7
Analysis Score3.53.41.13.33.4
Community Score3.03.72.22.62.7
Dividend Score0.00.00.00.00.0
Ownership Score1.70.81.70.01.7
Earnings & Valuation Score1.30.63.10.60.6
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyBuy
Consensus Price Target$37.50$49.25$11.40$32.17$26.00
% Upside from Price Target27.64% upside128.01% upside3.73% upside62.79% upside40.69% upside
Trade Information
Market Cap$1.56 billion$1.49 billion$1.77 billion$1.79 billion$1.69 billion
Beta1.38N/A1.462.991.52
Average Volume576,357328,7682,012,390902,7921,041,654
Sales & Book Value
Annual Revenue$392.76 million$2.34 million$428.41 millionN/A$145.97 million
Price / Sales3.97635.934.13N/A11.61
Cashflow$2.60 per shareN/A$0.56 per shareN/AN/A
Price / Cash11.30N/A19.49N/AN/A
Book Value$11.35 per shareN/A($0.59) per share($1.21) per share$4.48 per share
Price / Book2.59-18.63N/A4.13
Profitability
Net Income$113.06 million$-116,480,000.00$21.50 million$-288,990,000.00$-204,750,000.00
EPS$2.10($2.36)$0.55($3.37)($2.50)
Trailing P/E Ratio12.19N/A15.93N/AN/A
Forward P/E Ratio18.59N/A9.56N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins27.09%N/A27.77%N/A-216.18%
Return on Equity (ROE)20.02%N/A-240.80%N/A-65.06%
Return on Assets (ROA)9.67%N/A27.05%-201.20%-49.14%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.53%0.28%71.91%N/AN/A
Current Ratio1.84%15.55%13.17%1.75%3.60%
Quick Ratio1.70%15.55%13.17%1.75%3.16%
Ownership Information
Institutional Ownership Percentage96.11%40.88%N/A33.77%99.01%
Insider Ownership Percentage6.57%N/A2.40%3.90%12.85%
Miscellaneous
Employees563208232214223
Shares Outstanding53.02 million68.89 million160.96 million90.80 million91.68 million
Next Earnings Date8/17/2021 (Estimated)8/17/2021 (Estimated)8/5/2021 (Estimated)5/11/2021 (Confirmed)8/4/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
HRTX Stock Forecast 2021: Heron Therapeutics Inc. Remains Hot with 72.9% UpsideHRTX Stock Forecast 2021: Heron Therapeutics Inc. Remains Hot with 72.9% Upside
marketingsentinel.com - May 11 at 1:06 PM
Heron Therapeutics (NASDAQ:HRTX) Announces  Earnings Results, Misses Estimates By $0.06 EPSHeron Therapeutics (NASDAQ:HRTX) Announces Earnings Results, Misses Estimates By $0.06 EPS
americanbankingnews.com - May 10 at 9:06 PM
Heron Therapeutics: Q1 Earnings SnapshotHeron Therapeutics: Q1 Earnings Snapshot
sfgate.com - May 10 at 4:15 PM
Heron Therapeutics Inc Posts Quarterly Loss Per Share $0.58Heron Therapeutics Inc Posts Quarterly Loss Per Share $0.58
cmlviz.com - May 10 at 4:15 PM
Heron Therapeutics: Q1 Earnings Snapshot | Raleigh News & ObserverHeron Therapeutics: Q1 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - May 10 at 4:15 PM
Heron Stock Trading Higher After Q1 Earnings, Ahead Of HTX-011 Decision Scheduled This WeekHeron Stock Trading Higher After Q1 Earnings, Ahead Of HTX-011 Decision Scheduled This Week
benzinga.com - May 10 at 4:15 PM
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Recent Corporate UpdatesHeron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Recent Corporate Updates
finance.yahoo.com - May 10 at 4:15 PM
Heron Therapeutics (HRTX) Reports Q1 Loss, Misses Revenue EstimatesHeron Therapeutics (HRTX) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 10 at 4:15 PM
Why Heron Therapeutics Stock Jumped TodayWhy Heron Therapeutics Stock Jumped Today
finance.yahoo.com - May 10 at 4:15 PM
Heron Therapeutics (NASDAQ:HRTX) Stock Price Up 6.4%Heron Therapeutics (NASDAQ:HRTX) Stock Price Up 6.4%
americanbankingnews.com - May 10 at 3:47 PM
Is Heron Therapeutics Inc. (NASDAQ:HRTX) Still A Hot Buy?Is Heron Therapeutics Inc. (NASDAQ:HRTX) Still A Hot Buy?
stocksregister.com - May 8 at 3:03 PM
Heron Therapeutics, Inc. (NASDAQ:HRTX) Forecasted to Post FY2022 Earnings of ($1.43) Per ShareHeron Therapeutics, Inc. (NASDAQ:HRTX) Forecasted to Post FY2022 Earnings of ($1.43) Per Share
americanbankingnews.com - May 6 at 11:16 AM
HRTX Makes Notable Cross Below Critical Moving AverageHRTX Makes Notable Cross Below Critical Moving Average
nasdaq.com - May 4 at 1:32 PM
Heron Therapeutics (NASDAQ:HRTX) Shares Gap Down to $17.36Heron Therapeutics (NASDAQ:HRTX) Shares Gap Down to $17.36
americanbankingnews.com - May 4 at 11:40 AM
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Buy" by BrokeragesHeron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - May 4 at 10:52 AM
Heron Therapeutics, Inc. (NASDAQ:HRTX) Rose 28.38% From Its 52-Week Low; YTD Numbers Fall -17.41% – Here Are Some Things To Keep In MindHeron Therapeutics, Inc. (NASDAQ:HRTX) Rose 28.38% From Its 52-Week Low; YTD Numbers Fall -17.41% – Here Are Some Things To Keep In Mind
marketingsentinel.com - May 1 at 9:17 AM
Traders Buy High Volume of Call Options on Heron Therapeutics (NASDAQ:HRTX)Traders Buy High Volume of Call Options on Heron Therapeutics (NASDAQ:HRTX)
americanbankingnews.com - April 28 at 6:20 PM
Will Heron Therapeutics (HRTX) Report Negative Q1 Earnings? What You Should KnowWill Heron Therapeutics (HRTX) Report Negative Q1 Earnings? What You Should Know
finance.yahoo.com - April 28 at 1:40 PM
Heron Therapeutics(NASDAQ:HRTX) Share Price Is Down 43% Over The Past Three Years.Heron Therapeutics'(NASDAQ:HRTX) Share Price Is Down 43% Over The Past Three Years.
nasdaq.com - April 28 at 8:39 AM
Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected to Post Earnings of -$0.57 Per ShareHeron Therapeutics, Inc. (NASDAQ:HRTX) Expected to Post Earnings of -$0.57 Per Share
americanbankingnews.com - April 26 at 4:24 PM
Heron Therapeutics, Inc. (NASDAQ:HRTX) Is Expected To Breakeven In The Near FutureHeron Therapeutics, Inc. (NASDAQ:HRTX) Is Expected To Breakeven In The Near Future
finance.yahoo.com - April 22 at 9:29 AM
Heron Therapeutics (NASDAQ:HRTX) Trading Up 2.9%Heron Therapeutics (NASDAQ:HRTX) Trading Up 2.9%
americanbankingnews.com - April 20 at 2:44 PM
HRTX Jun 2021 15.000 callHRTX Jun 2021 15.000 call
ca.finance.yahoo.com - April 18 at 10:53 PM
HRTX Sep 2021 11.000 putHRTX Sep 2021 11.000 put
ca.finance.yahoo.com - April 18 at 10:53 PM
Do Options Traders Know Something About Heron Therapeutics (HRTX) Stock We Dont?Do Options Traders Know Something About Heron Therapeutics (HRTX) Stock We Don't?
msn.com - April 7 at 9:44 AM
DateCompanyBrokerageAction
4/19/2021Supernus PharmaceuticalsJefferies Financial GroupUpgrade
2/3/2021Supernus PharmaceuticalsPiper SandlerBoost Price Target
4/16/2020Supernus PharmaceuticalsStifel NicolausLower Price Target
11/8/2019Supernus PharmaceuticalsBerenberg BankDowngrade
8/7/2019Supernus PharmaceuticalsCowenSet Price Target
8/7/2019Supernus PharmaceuticalsMizuhoReiterated Rating
5/8/2019Supernus PharmaceuticalsCantor FitzgeraldSet Price Target
3/4/2019Supernus PharmaceuticalsB. RileySet Price Target
1/16/2019Supernus PharmaceuticalsPiper Jaffray CompaniesSet Price Target
5/10/2021ADC TherapeuticsMorgan StanleyLower Price Target
5/3/2021ADC TherapeuticsHC WainwrightBoost Price Target
6/9/2020ADC TherapeuticsBank of AmericaInitiated Coverage
11/6/2020Ironwood PharmaceuticalsCredit Suisse GroupBoost Price Target
9/30/2020Ironwood PharmaceuticalsWells Fargo & CompanyDowngrade
8/3/2020Ironwood PharmaceuticalsNorthland SecuritiesReiterated Rating
7/31/2019Ironwood PharmaceuticalsWedbushBoost Price Target
5/3/2021Myovant SciencesJPMorgan Chase & Co.Lower Price Target
2/12/2021Myovant SciencesSVB LeerinkLower Price Target
1/6/2021Myovant SciencesThe Goldman Sachs GroupDowngrade
12/21/2020Myovant SciencesRobert W. BairdBoost Price Target
6/23/2020Myovant SciencesEvercore ISIBoost Price Target
6/2/2020Myovant SciencesCitigroupBoost Price Target
11/19/2019Myovant SciencesJMP SecuritiesReiterated Rating
2/13/2019Myovant SciencesBarclaysUpgrade
5/26/2020Heron TherapeuticsGuggenheimInitiated Coverage
5/18/2020Heron TherapeuticsFIXInitiated Coverage
4/15/2020Heron TherapeuticsNeedham & Company LLCReiterated Rating
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.